BloombergBloomberg

A breakthrough on Alzheimer's is closer than ever

By Lisa Jarvis

03 May 2023 · 3 min read

Editor's Note

Eli Lilly's experimental drug clears away the amyloid plaques known to coat the brains of people with Alzheimer's. Bloomberg reports on recent developments in the field and its next challenge.

New data for Eli Lilly's Alzheimer's treatment donanemab is a big win for patients and their families after decades of disappointments. Perhaps as important, it will help overcome the field's next challenge: getting insurers to pay for the drugs.

Lilly's experimental drug works by clearing away the amyloid plaques known to coat the brains of people with Alzheimer's. Monthly infusions slowed the relentless cognitive decline in Alzheimer's by 35% during the 18-month study of people in the early stages of the disease.

Sign in to informed

  • Curated articles from premium publishers, ad-free
  • Concise Daily Briefs with quick-read summaries
  • Read, listen, save for later, or enjoy offline
  • Enjoy personalized content